Entries by Sarah Russo

Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.

Authors: Ruth E. Cooper, Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi, Philip Asherson
European Neuropsychopharmacology, August 2017

Adults with ADHD describe self-medicating with cannabis, with some reporting a preference for cannabis over ADHD medications. A small number of psychiatrists in the US prescribe cannabis medication for ADHD, despite there being no evidence from randomised controlled studies…

Marijuana and pregnancy: objective education is good, but biased education is not.

Authors: Ciara A. Torres, Carl L. Hart
American Journal of Obstetrics and Gynecology, August 2017

To the Editors: We read with interest the article by Chasnoff, 1 which concluded that physicians should be educated about the negative effects of marijuana use during pregnancy and should discourage its use by pregnant women and women considering becoming pregnant. In our view…

,

Spatial distribution of cannabinoid receptor type 1 (CB1) in normal canine central and peripheral nervous system.

Authors: Jessica Freundt-Revilla, Kristel Kegler, Wolfgang Baumgärtner, Andrea Tipold
PLoS One, 10 July 2017

The endocannabinoid system is a regulatory pathway consisting of two main types of cannabinoid receptors (CB1 and CB2) and their endogenous ligands, the endocannabinoids. The CB1 receptor is highly expressed in the central and peripheral nervous systems (PNS) in mammalians and…

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.

Authors: Kerstin Iffland, Franjo Grotenhermen
Cannabis and Cannabinoid Research, 1 June 2017

Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with o…

Effects of Marijuana on Mental Health: Depression.

Authors: Susan A. Stoner
Alcohol & Drug Abuse Institute, University of Washington, June 2017

THC and CBD appear to have antidepressant-like effects in animal models at certain doses but not others. Marijuana has been associated with diminished motivation, but a distinct “cannabis amotivational syndrome” has yet to be substantiated. Studies looking at whether marijuana…

A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice

Authors: Andras Bilkei-Gorzo, Onder Albayram, Astrid Draffehn, Kerstin Michel, Anastasia Piyanova, Hannah Oppenheimer, Mona Dvir-Ginzberg, Ildiko Rácz, Thomas Ulas, Sophie Imbeault, Itai Bab, Joachim L Schultze, Andreas Zimmer
Nature Medicine, 8 May 2017

The balance between detrimental, pro-aging, often stochastic processes and counteracting homeostatic mechanisms largely determines the progression of aging. There is substantial evidence suggesting that the endocannabinoid system (ECS) is part of the latter system because it m…

Cannabinoids in treatment-resistant epilepsy: A review.

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

An update on the advancements in the treatment of agitation in Alzheimer’s disease

Authors: Assaf Shelef, Yoram Barak, Uri Berger, Diana Paleacu, Shelly Tadger, Igor Plopsky, Yehuda Baruch
Expert Opinion on Pharmacotherapy, April 2017

Neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) are associated with significant negative outcomes for patients and their caregivers. Agitation, one of the most distressing NPS, lacks safe and effective long term interventions. Nonpharmacological interventions are s…

,

In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease

Authors: Georgia Watt, Tim Karl
Frontiers in Pharmacology, 3 February 2017

Alzheimer’s disease (AD) is a debilitating neurodegenerative disease that is affecting an increasing number of people. It is characterized by the accumulation of amyloid-β and tau hyperphosphorylation as well as neuroinflammation and oxidative stress. Current AD treatments do…

Cannabinoids in Parkinson’s Disease.

Authors: Mario Stampanoni Bassi, Andrea Sancesario, Roberta Morace, Diego Centonze, Ennio Iezzi
Cannabis and Cannabinoid Research, February 2017

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably compl…

Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?

Authors: Renata Androvicova, Jiri Horacek, Tibor Stark, Filippo Drago, Vincenzo Micale
Pharmacological Research, January 2017

The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana’s psychoactive ingredient Δ9-tetrahydrocannabinol (Δ9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis…

Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.

Authors: Javier Fernández-Ruiz, María Gómez-Ruiz, Concepción García, Mariluz Hernández, José A. Ramos
Methods in Enzymology, 2017

The increase in lifespan during the last 50 years, mainly in developed countries, has originated a progressive elevation in the incidence of chronic neurodegenerative disorders, for which aging is the key risk factor. This fact will definitively become the major biomedical cha…